The bronchodilator response to salmeterol is maintained with regular, long-term use in patients with COPD

Pulmonary Pharmacology and Therapeutics

Volumn 18, Issue 1, 2005, Pages 19-22

  Hanania, N A ^a   Kalberg, C ^b   Yates, J ^b   Emmett, A ^b   Horstman, D ^b   Knobil, K ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Bronchodilator; Chronic obstructive pulmonary disease (COPD); Long acting beta 2 agonist (LABA); Salmeterol

Indexed keywords

FLUTICASONE PROPIONATE PLUS SALMETEROL; PLACEBO; SALMETEROL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DOSE RESPONSE; DRUG TOLERANCE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL;

ADMINISTRATION, INHALATION; ALBUTEROL; ANDROSTADIENES; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; EQUIPMENT AND SUPPLIES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; POWDERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TIME FACTORS;

EID: 10644234868     PISSN: 10945539     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pupt.2004.07.005     Document Type: Article

References (13)

1. GOLD Global initiative for chronic obstructive lung disease: global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease Am J Respir Crit Care Med 163 2001 1256 1276
2. D.A. Mahler, J.F. Donohue, R.A. Barbee, M.D. Goldman, N.J. Gross, and M.E. Wisniewski Efficacy of salmeterol xinafoate in the treatment of COPD Chest 115 4 1999 957 965
3. 2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 163 5 2001 1087 1092
4. G. Boyd, A.H. Morice, J.C. Pounsford, M. Siebert, N. Peslis, and C. Crawford An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) Eur Respir J 10 4 1997 815 821
5. D.A. Mahler, P. Wire, D. Horstman, C.N. Chang, J. Yates, and T. Fischer Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease Am J Respir Crit Care Med 166 8 2002 1084 1091
6. N.A. Hanania, P. Darken, D. Horstman, M.D. Reisner, B. Lee, and S. Davis The efficacy and safety of fluticasone propionate 250 μg/salmeterol 50 μg combined in the Diskus inhaler for the treatment of chronic obstructive pulmonary disease Chest 124 2003 834 843
7. A.T. Society Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma Am Rev Respir Dis 152 1995 S77 120
8. P. van Elteren The combination of independant two-sample tests of Wilcoxon Bull Int Stat Inst 37 1958 357 361
9. J.F. Donohue, S. Menjoge, and S. Kesten Tolerance to bronchodilating effects of salmeterol in COPD Respir Med 97 9 2003 1014 1020
10. P. Calverley, R. Pauwels, J. Vestbo, P. Jones, N. Pride, and A. Gulsvik Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial Lancet 361 9356 2003 449 456
11. R. Stockley, L. Rice, and N. Chopra Salmeterol added to usual therapy gives a rapid improvement in lung function that is sustained at 6 and 12 months in patients with COPD Am J Respir Crit Care Med 167 7 2003 A93
12. R. Stockley, P.J. Whitehead, M.K. Williams, and G. Hagan Serevent significantly increased trough FEV1 in COPD up to 12 months without loss of effect Am J Respir Crit Care Med 167 7 2003 A95
13. R. Stockley, E.A. Davis, S. Sondhi, and L. Rice Salmeterol provides sustained health status improvement over 12 months in patients with COPD Eur Respir J 20 Suppl 38 2002 S241